Last updated: 2026/06/01
Homepage
Last updated: 2026/06/01
- Home
- Products
- Contrast Media
- Anti-Diabetic Drugs
- Anti-Anxiety Drug
- API
- Intermediates
- Iohexol Intermediate 5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
- Iohexol/Ioversol Intermediate 5-Amino-N, N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
- Ioversol Intermediate (order based) N, N'-Bis(2,3-dihydroxypropyl)-5-(glycoloylamino)-2,4,6-triiodoisophthalamide
- Iopamidol Intermediate (order based) 5-Amino-2,4,6-triiodoisophthalic acid
- Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride
- Diethylenetriaminepentaacetic acid (DTPA)
- Excipients
- Specialities
- Company
- News
- Corporate News
- Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets
- CPHI China 2024 Invitation
- [New Product] Beilu Pharma Secures Approval for Iomeprol Injection
- Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement
- Reasonable Use of Iohexol Reasonable Use of Iohexol Adverse Reactions
- Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
- Invitation Letter
- Beilu Pharmaceutical's Iohexol Injection Receives Marketing Authorization in Hungary
- Beilu Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Indian Registration Certificate
- Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement
- [New Product] Beilu Pharmaceutical's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Approved
- New Product Approval: Beilu Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets
- [New Product] Beilu Pharma’s Iopromide Injection Obtains Approval
- CPHI China 2026
- [New Product] Beilu Pharma's Mupirocin Ointment Granted NMPA Approval
- Announcement: Beilu Pharma’s Gadobutrol API Receives CEP Certificate
- Congratulations: Beilu Pharma's Iodixanol Injection Passed the Consistency Evaluation for Generic Drugs
- Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement
- 109 Million! Subsidiary Hichi Pharmaceutical Completed a New Round of Financing to Help Increase Profitability
- New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation
- Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!
- Beilu Pharma Invested 192 Million Yuan In Cangzhou Raw Material Production Project
- Beilu Pharma's Gadobutrol Injection Has Been Approved By NMPA
- Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched
- Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong
- Beilu was Awarded the Title of A-class enterprise for safety production
- Beilu Pharmaceutical has Won the '2022 China Top 500 Corporate Philanthropy' Award!
- Congratulations: Beilu Pharma's Iohexol Injection Passed the Consistency Evaluation for Generic Drugs
- Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit
- Big News! Beilu Pharmaceutical Acquired Hichi Pharmaceutical to Strengthen the Layout of Contrast Agent APIs
- Beilu Pharmaceutical's Repaglinide Tablets Receive Generic Drug Bioequivalence Assessment
- Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation
- Beilu was awarded the “Top 100 Small and Medium-sized Private Enterprises in Beijing” and “Top 100 Private Enterprises in Beijing for Social Responsibility”
- Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement
- Beilu's Iopamidol Injection Won the Bid for China's Pharmaceutical Centralized Procurement
- Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.
- Beilu Pharma Established a Wholly-owned R&D Subsidiary
- Iohexol from Beilu Pharma's holding subsidiary Zhejiang Hichi Pharmaceutical Corporation Limited has been registered with CDSCO
- CPhl China 2023 Invitation
- Beijing Beilu Pharmaceutical Invites You to Participate in the 2023 Beijing International LIfe and Health Industry Expo
- Beilu Pharmaceutical Has Won the
- Good News: Beilu Pharmaceutical's Jiuwei Zhenxin Granules Included in 18 Industry Consensus Guidelines
- Foreign Journalists Visit Beilu Pharmaceutical to Learn about Beijing's Green Development
- CPHI WORLDWIDE 2023
- Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.
- Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 20 Industry Guidelines Consensus Teaching Materials
- Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 21 Industry Guidelines Consensus Teaching Materials
- Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"
- Beilu Pharmaceutical's Gadobenate Dimeglumine Injection Passes Generic Drug Consistency Evaluation!
- Beilu Pharmaceutical Officially Acquires Tianyuan Pharmaceutical, Continues to Advance the Strategic Layout of Traditional Chinese Medicine
- 【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved
- 【Good News】Beilu Pharmaceutical once again honored as "Beijing Advanced Unit for Daily Monitoring of Adverse Drug Reactions"
- 【New Product】Beilu Pharmaceutical's Gadoteric Acid Meglumine Injection and API Approved
- Hichi Pharmaceutical's Iodixanol API Approved for Market
- Beilu Pharmaceutical Obtains GMP Certification from ANVISA
- Beilu Pharma's Contrast Media Production Line Passed EU GMP Certification.
- Beilu Pharmaceutical and Chengqingtang Traditional Chinese Medicine Establish Strategic Cooperation
- Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Korean Registration Certificate
- Beilu Pharmaceutical Subsidiary Hichi Pharmaceutical's Iopamidol Approved for Market Release
- Beilu Pharmaceutical's Sees Strong Start to 2025 with Q1 Revenue and Profit Growth
- Beilu Pharmaceutical's 2024 Annual Online Performance Presentation on May 9
- Beilu Pharmaceutical Wins Emerging Pharmaceutical Internationalization Award at CPHI China
- Gadobenate Dimeglumine Injection and Gadopentetate Dimeglumine Injections Proposed for Selection in Xinjiang Uygur Autonomous Region's 26-Province Alliance Centralized Volume-Based Procurement
- Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical: Iopromide API Approved for Market Launch
- Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API
- Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)
- [News] Beilu Pharmaceutical's Wholly-owned Subsidiary, Hong Kong Yuanzhi, Obtains Hong Kong Proprietary Chinese Medicine Registration Certificate for Jiuwei Sleep-Aid Granules
- [Good News] Beilu Pharma's Gadobutrol API Approved
- [New Product] Beilu Pharma's Ioversol Injection Receives Approval
- Beilu Pharma's Dyclonine Hydrochloride Chemical Active Pharmaceutical Ingredient (API) Approved by NMPA
- Blog Update
- Contact Us